drugset / Trial / NCT00988195
Study of Pegylated Human Recombinant Arginase for Liver Cancer
Phase 1
Completed
15 enrolled
Bio-Cancer Treatment International Limited
Chinese University of Hong Kong · collabThe University of Hong Kong · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether recombinant human arginase (PEG-BCT-100) is safe and effective in the treatment of advanced hepatocellular carcinoma (HCC).
Timeline
- Start
- 2008-05
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegylated Recombinant Human Arginase I | Protein / enzyme biologic | 500 iu/kg | Intravenous |
| Subject | Pegylated Recombinant Human Arginase I | Protein / enzyme biologic | 5000 iu/kg | Intravenous |
| Background | Doxorubicin | Other / unclassified | — | — |